Taiho Oncology, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2002-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.taihooncology.com
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
- Conditions
- Advanced/Metastatic Cancer
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06506955
- Locations
- 🇫🇷
Institut Paoli-Calmettes, Marseille, France
🇰🇷Severance Hospital, Seoul, Korea, Republic of
🇪🇸Hospital Universitari, Vall d'Hebron, Barcelona, Spain
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
- Conditions
- Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT05973773
- Locations
- 🇧🇷
Clínica Neoplasias Litoral, Itajaí, Santa Catatina, Brazil
🇹🇷Trakya Üniversitesi Sa?l?k Ara?t?rma ve Uygulama Merkezi, Edirne, Turkey
🇹🇷Ankara Il Saglik Mudurlugu SBU Gulhane Egitim Ve Arastirma Hastanesi, Etlik, Turkey
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
- Conditions
- Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT05967689
- Locations
- 🇮🇹
Azienda Unità Sanitaria Locale - Piacenza, Piacenza, Italy
🇪🇸Hospital Quirónsalud Barcelona, Barcelona, Spain
🇪🇸Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
- Conditions
- Esophageal Squamous Cell CancerLocally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal CancerSiewert Type 1 GEJ CancerPancreatic CancerEsophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT05945823
- Locations
- 🇺🇸
University of California Los Angeles UCLA - Cancer Care - Santa Monica, Santa Monica, California, United States
🇺🇸Rocky Mountain Cancer Centers Midtown, Denver, Colorado, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
A Study of TAS3351 in NSCLC Patients With EGFRmt
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: TAS3351 oral administration
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05765734
- Locations
- 🇺🇸
Georgetown University - Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
- Conditions
- Advanced CholangiocarcinomaFGFR2 FusionsGene Rearrangement
- Interventions
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05727176
- Locations
- 🇪🇸
Hospital Universitario 12 de octubre, Madrid, Spain
🇪🇸Clinica Universidad de Navarra, Pamplona, Spain
🇦🇺St John of God Subiaco Hospital, Subiaco, Western Australia, Australia
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
- Conditions
- Relapsed/Refractory Peripheral T-cell Lymphoma
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT05403450
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇫🇷Institut Paoli-Calmettes, Marseille, France
🇦🇺Concord Hospital, Concord, New South Wales, Australia
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
- Conditions
- Breast CancerSolid TumorGlioblastomaNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04982926
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇫🇷CLCC Gustave Roussy, Villejuif, Cedex, France
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
- Conditions
- KRAS Gene MutationAdvanced or Metastatic Solid Tumors Irrespective of Gene AlterationsNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04965818
- Locations
- 🇺🇸
Community Cancer Center North, Indianapolis, Indiana, United States
🇺🇸University of California Los Angeles UCLA Cancer, Santa Monica, California, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04953910
- Locations
- 🇺🇸
MD Anderson, Houston, Texas, United States
🇦🇲Erebuni Medical Center, Yerevan, Armenia
🇦🇲Hematology Center After Prof. R. Yeolyan (Adult Blood Disorders), Yerevan, Armenia